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ABSTRACT 
Objective: Osteoarthritis (OA) is a progressive chronic disease with the loss of articular cartilage. In managing OA, inadequate pain relief (IPR) 
often occurs, particularly with a single non steroidal anti-inflammatory drugs (NSAIDs) therapy. In this research, pain outcome of OA patients 
treated with a combination of diacerein and meloxicam vs meloxicam alone was evaluated.  
Methods: This research was conducted at rumah sakit umum daerah (RSUD) Dr. Mohammad Soewandhie Surabaya by using randomized controlled 
trial (RCT) design. Pain outcome was evaluated by pain intensity and area under the curve (AUC) of pain score in week 0-4th.  
Results: There were a significantly different (p<0.05) in pain intensity seen in 3rd and 4th weeks after treated with a combination of diacerein and 
meloxicam, and with meloxicam only. However, there were no different in AUC pain score between combination and single therapy.  
Conclusion: Combination therapy of diacerein and meloxicam was more effective than meloxicam alone. A significant effect of a combination 
therapy of diacerein and meloxicam occurred at 3rd weeks. The prolong study in order to get the differences in AUC pain score are needed. 
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INTRODUCTION 
Osteoarthritis (OA) is a progressive chronic disease that was 
characterized by loss of articular cartilage [1]. World Health 
Organization data showed that OA is still one of the ten most 
diseases that caused disability in developed countries. Prevalence of 
radiological knee OA in Indonesia was 15.5% in men and 12.7% in 
women between 40-60 y of age [2]. 
Osteteoarthritic pain is a chronic pain. Its remission for longer 
period is difficult [3]. Osteoarthritis and pain symptom experienced 
by patients have bad effects. Walking limitations have an impact on 
activities of daily living, which 11% of patients need assistance to do 
personal care [1]. Osteoarthritis patients also have limitations to 
work [4]. A disability that occurs in OA patients is associated with 
greater depression [5]. However, in its management, inadequate 
pain relief (IPR) was occurred in 54-64% of patients. Satisfaction 
and quality of life become worse because of IPR [6–8]. 
Among the study of OA therapy, non steroidal anti-inflammatory 
drugs (NSAIDs) are the most widely prescribed medication [6–8], 
but they often cause a dissatisfaction in the treatment of pain [9]. 
The inability of NSAIDs in overcoming the pain can be caused by the 
analgesic ceiling effect. In addition, OA is a complex process 
involving a variety of mechanisms [9]. The combination of analgesics 
that works by different mechanism may lead to a synergistic effect in 
the treatment of OA [10, 11]. Non steroidal anti-inflammatory drugs 
also do not affect the underlying pathogenesis of the disease [12], so 
they have a minimal role in modifying the course of the disease and 
improve the quality of life. 
A combination drug that can be offered to overcome OA is diacerein 
and meloxicam. Diacerein is an interleukin 1(IL-1) inhibitor 
developed for the treatment of OA. Diacerein has efficacy in terms of 
functional manifestations and structural components of OA [13–15]. 
It plays an important role in cartilage degradation and stimulation of 
nociceptive pathways. This mediator shows potent bioactivity in 
inhibiting synthesis of extracellular matrix (ECM), promoting 
cartilage damage, and suppressing the expression of an important 
component of ECM in chondrocytes [16]. 
Although diacerein can contribute to overcoming the problem of OA, 
some studies are still debating its benefit. Several randomized 
controlled trials (RCTs) and meta-analysis studies showed the 
benefits of diacerein in the treatment of OA and others studies in the 
Cochrane library declared the absence of significant benefit of 
diacerein [13, 17–22]. Diacerein was reported having slow-acting 
properties. The long onset of diacerein cause pain management with 
diacerein must be combined with other analgesics, such as NSAIDs 
during the first month of treatment [14]. One of the NSAIDs that can 
be used is meloxicam that showed benefit in overcoming the pain of 
OA and rheumathoid disorder [23–26]. Meloxicam has a long half-
life (20-24 h) so the using frequency was lower and easier for 
patients [27]. Based on the above, pain outcomes of OA patients 
receiving combination therapy of diacerein and meloxicam, and 
meloxicam alone were compared in this study. 
MATERIALS AND METHODS 
Study design  
This was an open-label, RCT study. The study was conducted during the 
period January 2016-March 2016 at rumah sakit umum daerah (RSUD) 
Dr. Mohammad Soewandhie Surabaya. The patient was provided written 
informed consent. The study was approved by Badan Koordinasi 
Pendidikan RSUD Dr. Mohammad Soewandhie Surabaya and Badan 
Kesatuan Bangsa, Politik, dan Perlindungan Masyarakat Kota Surabaya 
with approval number 070/2554/436.7.8/2016. The consecutive 
sampling method was used to get participant. 
Before intervention was started, screening visit was conducted to 
determine who will be included in the randomization. At the time of 
screening, washout was conducted for the analgesic that was used 
by patients. The washout period was conducted over 5 × t½ of the 
drug. If patients experienced pain during the washout period, the 
patients would be given rescue medication (paracetamol 500 mg, 
maximum 4 g/d). After a washout period, and the patient 
experienced pain at least 24 h with scale ≥ 4, randomization was 
conducted with blocked randomization method. 
Participants in the study were divided into two groups, to receive 
the combination of diacerein (Artoflam®) 50 mg once daily and 
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meloxicam 15 mg once daily or to receive meloxicam 15 mg once 
daily. Drug administration was conducted for 4 w. Follow-up was 
done every week. Patients were asked to record date and a missed 
dose, other drugs taken, and changes in the drugs taken. Patients 
were asked to return the blister of drugs that have been taken and 
the rest of the drug (both drugs from our study or other drugs 
consumed by the participant).  
Compliance was calculated by comparing the actual amount of drug 
taken with drugs should be taken during the treatment period. 
Patients who missed>20% of the drugs were categorized as non-
compliant. Patients were discontinued from the study if there were 
any violation in the criteria of the study, non-compliance with the 
study protocol, or the incidence of severe side effects. 
Patient 
The population was outpatients of the orthopedy clinic in RSUD Dr. 
Mohammad Soewandhie Surabaya. Patients were eligible for the study 
if they were diagnosed with OA knee by orthopedic specialists, 18-75 y 
old, had moderate pain when they did not use analgesic (pain score ≥ 4 
with 0-10 scale), body mass index (BMI) ≤ 39 kg/m2, and agreed to 
follow the study by signing an informed consent. The definition of 
knee OA in this study is OA that met clinical criteria and radiological 
criteria based on Indonesian Rheumatism Association [2]. 
Exclusion criteria were patient with malignancy; pregnant or using 
hormonal contraceptive; bleeding disorder or using anticoagulant, 
or aspirin with daily dose more than 325 mg; uncontrolled 
hypertension (diastolic>95 or systolic>165), heart failure, or 
unstable angina; liver and kidney disorder (creatinine clearance ≤ 
30 ml/min that was calculated with Cockroft-Gault formula); 
psychiatric disorders, using antidepressants, anticonvulsants, 
antipsychotics, sedatives, or muscle relaxant; drug dependency, drug 
abuse, or alcohol abuse (≥ 3 glasses/d); history of allergy with drug 
used in this study; reading, hearing, and speaking inability. 
Evaluation of pain outcome 
Pain intensity was measured by a combination of Wong Backer Face 
Rating Scale (WBFPRS) and numeric rating scale (NRS) tools (fig. 1). 
Patients were asked to circle one number between 0 and 10 that was 
the most appropriate to describe the intensity of their pain. Pain 
intensity was assessed at baseline and every week until the 4th w. 
The area under the curve (AUC) of pain intensity on each subject 
was calculated up to 4 w of observation using trapezoidal rule. 
 
 
Fig. 1: Combination of WBFPRS and NRS tools 
Statistical analysis 
Data were analyzed with per protocol method. Normality test was 
analyzed with Shapiro-Wilk test. Data followed a normal curve if 
p>0.05. Homogeneity test was done by Levene's test. Data were 
homogeneous if p>0.05. Pain intensity was analyzed using the 
following method. 
1. Paired-sample t-test or Willcoxon signed rank test was used to 
compare the efficacy of each group with baseline. 
2. Independent-samples t-test or Mann-Whitney U test was used to 
compare the efficacy between the group receiving combination of 
diacerein and meloxicam, and meloxicam alone  
For all test, data between different groups were significant if p<0.05 
RESULTS  
A total 68 subject were included in this study. Six subjects were 
excluded as they used others analgesics, had low compliance, 
experienced adverse drug reaction (ADR) that could not be 
tolerated, consumed other OA drug, and experienced getting worse 
pain. The remaining 62 patients completed the study and included in 
the analysis (fig. 2.) 
 
Table 1: Demographic and clinical characteristics of participant 
No Patients characteristics Combination of diacerein dan meloxicam (N=30) Meloxicam alone 
(N=32) 
p 
1 Gender Female Σ (%)  24 (80.0%) 25 (78.1%) 1.000 
Male Σ (%) 6 (20.0%) 7 (21.9%) 
2 Age ≥ 60 y  16 (53.3%) 18 (56.3%) 1.000 
<60 y  14 (46.7%) 14 (43.8%) 
mean±SD (y) 61.13 ± 8.53 60.41 ± 7.69 0.860 
3 BMI  Normal weight Σ (%) 11 (36.7%) 6 (18.8%) 0.136 
Overweight Σ (%) 13 (43.4%) 13 (40.6%) 
Obese Σ (%) 6 (20.0%) 13(40.6%) 
4 Pain intensity mean±SD 5.93 ± 1.51 6.19 ± 1.42 0.498 
5 WOMAC score Pain (mean±SD)  8.07 ± 3.42 8.81 ± 3.04 0.660 
Stiffness (mean±SD)  3.90 ± 2.20 4.06 ± 1.70 0.971 
Physical function (mean±SD)  31.70 ± 11.74 34.34 ± 10.15 0.346 
Total (mean±SD)  43.67 ± 15.63 47.22 ± 13.15 0.339 
6 Menopausal status Menopause Σ (%) 20 (83.3%) 24 (96.0%) 0.189 
Not menopause Σ (%) 4 (16.7%) 1 (4.0%) 
7 OA grade 1 Σ (%) 2 (6.67%) 0 (0.0%) 0.212 
2 Σ (%) 8 (26.7%) 19 (59.4%) 
3 Σ (%) 16 (53.3%) 8 (25.0%) 
4 Σ (%) 4 (13.3%) 5 (15.6%) 
8 Duration of OA  ≥ 5 y Σ (%) 2 (6.7%) 1 (3.1%) 0.607 
<5 y Σ (%) 28 (93.3%) 31 (96.9%) 
mean±SD (years)  1.13 ± 1.80 0.75 ± 1.92 0.089 
9. Involved joints Unilateral 15 (50.0%) 12 (37.5%) 0.462 
Bilateral  15 (50.0%) 20 (62.5%) 
N: sample size, BMI: body mass index (normal weight ≥ 18 kg/m2 and<25 kg/m2; overweight ≥25 kg/m2 and<30 kg/m2; obese ≥30 kg/m2), 
WOMAC: The Western Ontario and McMaster Universities Arthritis Index 
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Fig. 2: Study design 
 
The demographic and baseline clinical characteristics of patients 
were shown in table 1. The two treatment groups were similar with 
regard to demographic data and baseline clinical characteristic. 
Pain outcome evaluation 
Pain score decreased significantly in all groups when compared to the 
baseline values of each group (p<0.05) after 4 w therapies (table 2). 
In the first week until 2nd w, the difference of pain score between 
the combination of meloxicam and diacerein, and meloxicam 
alone could not be seen. Those differences were seen at 3rdweeks 
(p<0.05). This difference was stable at the end of follow-up (4th 
w). There was no significant difference in AUC of pain intensity 
(table 3). 
DISCUSSION 
This study was designed to assess the efficacy of combination 
diacerein and meloxicam, and meloxicam alone. In addition, this 
study was designed to compare the efficacy of combination 
diacerein and meloxicam, and meloxicam alone after 4 w of 
therapy. 
In this study, meloxicam 15 mg/d has proven effective to give a 
significant difference in the pain intensity between pre and post 
treatment after 4 w of therapy. Efficacy of meloxicam in 
overcoming pain in OA was supported by RCT study by Lund et 
al. (2000). That study showed that meloxicam 15 mg/d was 
significantly more effective to reduce pain than placebo after 3 w 
of treatment [24]. Randomized controlled trial study by Yocum 
et al. (2000) also showed the benefits of meloxicam 15 mg/d in 
patients with hip or knee OA compared to placebo. After 12 w of 
therapy, there were differences in pain intensity when moved 
(p<0.01) and pain at rest (p ≤ 0.001) [23]. The effect of 
meloxicam in reducing the pain intensity was caused by 
inhibition the cyclooxygenase (COX) enzyme. The COX-2 enzyme 
plays a role in the synthesis of prostaglandins, which were the 
mediators of pain [28]. 
 
Table 2: Statistical analysis results of pain intensity difference in pre and post treatment 
No Groups Pain intensity N mean±SD Sig 
1 Combination of diacerein and meloxicam Pre treatment 30 5.93±1.507 0.001* 
Post treatment 30 3.03±1.098 
2 Meloxicam alone Pre treatment 32 6.19±1.424 0.001* 
Post treatment 32 3.81±1.615  
N: sample size, Sig: significance, SD: Deviation standard, *: p<0.05 
 
Tabel 3: Statistical analysis results of pain intensity difference between combination of meloxicam and diacerein, and meloxicam alone 
No Time of follow-up Combination of diacerein dan meloxicam Meloxicam alone Sig 
mean±SD CI 95% mean±SD CI 95% 
1. Week 0 5.93±1.51 5.37-6.50 6.19±1.42 5.67-6.70 0.498 
2. Week 1 4.83±1.60 4.24-5.43 5.34±1.52 4.80-5.89 0.093 
3. Week 2 4.17±1.60 3.57-4.76 4.69±1.66 4.09-5.28 0.101 
4. Week 3 3.37±1.25 2.90-3.83 4.19±1.67 3.58-4.79 0.031* 
5. Week 4 3.03±1.10 2.62-3.44 3.81±1.62 3.23-4.39 0.035* 
6. AUC 16.85±5.22 14.90-18.80 19.22±5.97 17.0-21.37 0.064 
SD: Deviation standard, CI 95%: Confident Interval 95%, *: p<0.05 
 
In this study, the combination of meloxicam and diacerein were 
significantly effective to reduce pain intensity after 4 w. There were 
no studies that accessed the efficacy of the combination of 
meloxicam and diacerein. However, there was a similar study 
conducted by Gupta et al. (2012). In that study, 50 mg diacerein and 
other NSAIDs (diclofenac 75 mg/d), showed significantly different 
pain scores compared with baseline (after 16 w of therapy) [29]. 
Randomized controlled trial studies by Shafshak et al. (2012) 
showed administration diacerein (100 mg/d) and diclofenac giving 
the difference of pain intensity in the pre and post treatment, both at 
1 mo (p = 0.033) and 2 mo (p = 0.001) therapy [30]. A significant 
reduction effect in pain intensity after 4 w follow-up in this study 
was supported by the results of the other literature, which said that 
effects of diacerein appear 2-4 w after therapy, and were significant 
after 4-8 w [20]. Meloxicam reaches significant effects as an 
analgesic in 2nd-4th w [27]. 
Diacerein therapeutic effect on OA based on its ability to inhibit pain 
and also its affect on the structural components of the joint [15]. 
Diacerein activities were caused by its ability to inhibit IL-1. In the 
chronic inflammatory process, such as the OA, cells were under 
pressure and produced cytokines such as IL-1, IL-6, tumor necrosis 
factor-α (TNF-α) which can cause damage to cells and phospholipids 
membrane release [14]. In structural components, IL-1 plays an 
important role in cartilage degradation [16].  
When it is linked to the response to pain, mechanism of action of IL-
1β able can up-regulate of pro-nociceptive mediators, such as nerve 
growth factor (NGF), which was known as a neurotrophic factor that 
played an important role in the process of pain. Interleukin 1β can 
signal through a signal cascade that leads to the release and/or 
activation of nociceptive molecules such as prostaglandins, IL-6, 
substance P, and matrix metalloproteinase 9 (MMP 9). The action of 
IL-1β may also occur directly on nociceptors. The receptor for IL-1 is 
expressed in sensory neurons. Interleukin-1β can modulate 
neuronal accessibility to affect neuronal receptors such as sodium 
channels, gamma-aminobutyric acid (GABA), and n-methyl-d-
aspartate (NMDA) receptors [31]. With a complex mechanism, 
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diacerein can reduce the intensity of pain and prevents further 
cartilage damage. 
When it was compared with meloxicam alone, the combination of 
meloxicam and diacerein showed no significant difference in pain 
intensity at 1st and 2nd w. It could be caused by the onset of diacerein 
which was achieved at 2nd to 4th w after administration. The 
difference in pain intensity on both of groups can be observed at the 
3rd week 4th weeks. Meloxicam alone group had greater pain 
intensity than its combination with diacerein.  
When they were compared using AUC parameters, the combination 
of meloxicam and diacerein and meloxicam alone did not show a 
significant difference. Area under the curve data is the result of 
merging the intensity of pain from time to time. Pain intensity data 
can be transformed to the AUC to access the benefits of analgesic 
[32]. Compared with measurements at the end of study (EOS), the 
results of trials using the AUC provide smaller effect estimation but 
better precision. Area under the curve values gives the possibility to 
maintain the distinction treatment group by calculating the exact 
onset and offset of action of the drug. Trial with the rapid acting 
drug showed that AUC was more sensitive than EOS to detect 
treatment differences [33]. Analysis of the AUC was more stable and 
sensitive to see the interpatient difference than other 
measurements. Area under the curve described the cumulative 
response of an intervention, but did not provide information about 
the onset of analgesic effect [34]. 
Despite they have the different working mechanism and can support 
each other, the addition of diacerein to meloxicam therapy provided 
no significant difference in AUC of pain intensity. Several other 
studies supported the insignificant outcomes of pain intensity 
between the combination of diacerein and meloxicam with 
meloxicam alone. The results of this research were supported by a 
similar study conducted by Gupta et al. (2012). In that study, 
diacerein 50 mg in combination with other NSAIDs (diclofenac 75 
mg) per day has shown significant differences in pain scores after 16 
w of therapy compared with NSAIDs alone. That study did not 
explain the differences in pain scores over time between the 
combination group and single group. So, it was not known when 
these differences began to appear [29]. If it was assumed differences 
emerged at week 16th, the longer observation was needed in order to 
see the effect of the combination of meloxicam and diacerein. 
Randomized controlled trial study by Shafshak et al. (2012), in 
patients receiving diacerein 100 mg/d for 2 mo vs diclofenac vs 
diacerein, found that in all three groups, there were no significant 
difference in pain intensity, both at 1 mo (p = 0.493) and 2 mo (p = 
0.325) therapy [30]. Another study by Singh et al. (2012) also 
showed the comparison of addition NSAID (diclofenac) in patients 
with knee OA who consumed diacerein. The study was conducted for 
3 mo. The combination group used diacerein 50 mg/d in the first 
month, 2 × 50 mg/d in 2nd and 3rd and sustained release diclofenac 
75 mg/d from 1st to 3rd mo. Comparison group only used sustained 
release diclofenac 75 mg/d. After 3 mo, administration of diacerein 
and diclofenac showed a significant difference in pain intensity 
compared to diclofenac alone [35]. The difference above was 
appeared in a longer time (3 mo) compared to our study. That study 
did not explain about differences in pain scores over time, between 
the combination group and single froup, so it was unknown when 
these differences were begun. If it was assumed in Singh et al. study 
that differences were shown at the 3rd mo (week 12), we needed 
longer observation in order to see the different between the 
combination of diacerein and meloxicam, and meloxicam alone. In 
addition, that study used different dose every month (50 mg/d of 
diacerein in the first month, followed by 100 mg/d in the next 2 mo). 
This dose differences could affect the outcome differences. 
The difference of efficacy that was shown at 3rd and 4th w indicated 
that combination of meloxicam and diacerein had the potential 
benefits in the treatment of OA. Effect of diacerein was begun at 2nd 
to 4th w and significant at 4th-8th w [14]. Thus, we need longer 
observation up to 8 w in order to see the differences in the AUC of 
pain intensity. The differences in pain intensity between 2 groups 
become insignificant can be caused by small sample size, so we 
required the addition of large samples. In addition, different baseline 
characteristics among study could influence the results, such as 
gender, BMI, and duration of suffering from OA. 
There were differences in the proportion of men and women in the 
study conducted by Gupta et al. (2012) with our study. Our study 
was dominated by women (78.1%-80.00%), whereas in the study of 
Gupta et al., the proportion between male and female was 
comparable (male: female = 2: 3). Gender was known affecting 
response to pain experienced. The study that was conducted by 
Tonelli et al. (2011) showed that women had a greater pain intensity 
than men in patients with osteoarthritis (p = 0.04) [36]. Differences 
in BMI also can contribute to pain intensity difference in OA patients. 
A study by Oyeyemi et al. (2013) showed that BMI influenced the 
effectiveness of knee OA treatment [37]. The significant differences 
in pain intensity between the normal weight and overweight (p = 
0.016) patient and between normal weight and obese patient (p = 
0.005) was found. 
CONCLUSION 
Combination therapy of diacerein and meloxicam was more effective 
than meloxicam alone. A significant effect of a combination therapy 
of diacerein and meloxicam occurred at 3rd w. The prolong study in 
order to get the differences in AUC pain score are needed. In 
addition, the cost-effectiveness analysis was needed to see the 
benefit of that combination compared with the single therapy. 
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